Clinical-genomic characteristics of homologous recombination deficiency (HRD) in breast cancer: application model for practice

Background: Homologous recombination deficiency (HRD) affects breast cancer patients. Treatment guided by multigene testing may be particularly beneficial in HRD patients by using platinum-based drugs and poly ADP-ribose polymerase inhibitor (PARPi). However, the optimal method for HRD testing remai...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Du, Jinsui (VerfasserIn) , Zhu, Lizhe (VerfasserIn) , Duan, Chenglong (VerfasserIn) , Ma, Nan (VerfasserIn) , Zhou, Yudong (VerfasserIn) , Li, Danni (VerfasserIn) , Zhang, Jianing (VerfasserIn) , Zhang, Jiaqi (VerfasserIn) , Wang, Yalong (VerfasserIn) , Liu, Xi (VerfasserIn) , Ren, Yu (VerfasserIn) , Wang, Bin (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: April 7, 2025
In: European journal of medical research
Year: 2025, Jahrgang: 30, Heft: 1, Pages: 1-11
ISSN:2047-783X
DOI:10.1186/s40001-025-02520-8
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s40001-025-02520-8
Verlag, kostenfrei, Volltext: https://www.webofscience.com/api/gateway?GWVersion=2&SrcAuth=GetFTR&SrcApp=WOS&DestURL=https%3A%2F%2Fct.prod.getft.io%2FY2xhcml2YXRlLHNwcmluZ2VyLGh0dHBzOi8vbGluay5zcHJpbmdlci5jb20vY29udGVudC9wZGYvMTAuMTE4Ni9zNDAwMDEtMDI1LTAyNTIwLTgucGRm.T51EBsIo7KqWOZLPHRmkrjAcBAEKpy-JHwn2nWEPTZQ&DestApp=GetFTR&SrcItemId=WOS:001460732800002&SrcAppSID=EUW1ED0F20QEs703P6yZ24jUlIiPZ&HMAC=kPvXZAIUEdXdTP94vAx6lRjq2Amv98vQgZ2UqLCcqWw%3D
Volltext
Verfasserangaben:Jinsui Du, Lizhe Zhu, Chenglong Duan, Nan Ma, Yudong Zhou, Danni Li, Jianing Zhang, Jiaqi Zhang, Yalong Wang, Xi Liu, Yu Ren, Bin Wang

MARC

LEADER 00000naa a2200000 c 4500
001 1941614531
003 DE-627
005 20251119152218.0
007 cr uuu---uuuuu
008 251119s2025 xx |||||o 00| ||eng c
024 7 |a 10.1186/s40001-025-02520-8  |2 doi 
035 |a (DE-627)1941614531 
035 |a (DE-599)KXP1941614531 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Du, Jinsui  |e VerfasserIn  |0 (DE-588)1382003897  |0 (DE-627)1941615589  |4 aut 
245 1 0 |a Clinical-genomic characteristics of homologous recombination deficiency (HRD) in breast cancer  |b application model for practice  |c Jinsui Du, Lizhe Zhu, Chenglong Duan, Nan Ma, Yudong Zhou, Danni Li, Jianing Zhang, Jiaqi Zhang, Yalong Wang, Xi Liu, Yu Ren, Bin Wang 
264 1 |c April 7, 2025 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Background: Homologous recombination deficiency (HRD) affects breast cancer patients. Treatment guided by multigene testing may be particularly beneficial in HRD patients by using platinum-based drugs and poly ADP-ribose polymerase inhibitor (PARPi). However, the optimal method for HRD testing remains undetermined by guidelines or consensus and economic disparities limit the availability of genetic testing. Prioritizing HRD testing by clinical-genomic characteristics is critical for efficient utilization of healthcare resources and improved treatment accuracy.MethodsA total of 93 breast cancer patients who underwent HRD genetic testing were included in the study. According to the machine learning model called genomic scar (GS) HRD was defined as a genomic scar score (GSS) >= 50 or with deleterious mutation in the BRCA. Multivariate logistic regression analysis was employed to identify the clinical-pathological factors potentially associated with HRD. Suitable variables were selected to construct a predictive model, and the model's efficacy was evaluated using the area under the receiver operating characteristic (ROC) curve. Internal validation was performed using bootstrap resampling (500 replicates).ResultsPatients harboring pathogenic mutation in BRCA exhibited higher GSS (99.85 vs 36.90). HRD was not detected in 41.75% of patients, and 34.95% had HRD but no BRCA pathogenic mutations. HRD risk in human epidermal factor growth receptor 2 (HER2) low or positive was significantly lower compared to HER2 negative (OR: 0.390, 95% CI: 0.159-0.959, P = 0.040). High Ki- 67 index was strongly associated with HRD (OR: 28.434, 95% CI: 3.283-246.293, P = 0.002). Significant variations in GSS were observed based on estrogen receptor (ER) and progesterone receptor (PR) status, histological grade, and molecular types. The area under the ROC curve (AUC) of the combined prediction model combining HER2 status and Ki- 67 index was 0.749, and the accuracy of the model was further validated using bootstrap resampling (500 replicates), resulting in an AUC of 0.730, indicating a high predictive accuracy for HRD status.ConclusionsBRCA mutation status did not fully reflect HRD status. Patients with a negative HER2 status and high Ki- 67 index are more likely to exhibit positive results when undergoing HRD genetic testing. The ER, PR, HER- 2 status, Ki- 67 index, molecular typing, and histological grading may have a strong influence on the HRD status. 
650 4 |a <italic>BRCA</italic> 
650 4 |a BRCA1 
650 4 |a Breast cancer 
650 4 |a Clinical-genomic characteristics 
650 4 |a Genomic scar score 
650 4 |a Homologous recombination deficiency 
650 4 |a MUTATIONS 
650 4 |a PREVALENCE 
650 4 |a RISK 
650 4 |a SCORE 
700 1 |a Zhu, Lizhe  |e VerfasserIn  |4 aut 
700 1 |a Duan, Chenglong  |e VerfasserIn  |4 aut 
700 1 |a Ma, Nan  |d 1994-  |e VerfasserIn  |0 (DE-588)1319494781  |0 (DE-627)1880878364  |4 aut 
700 1 |a Zhou, Yudong  |e VerfasserIn  |4 aut 
700 1 |a Li, Danni  |e VerfasserIn  |4 aut 
700 1 |a Zhang, Jianing  |e VerfasserIn  |4 aut 
700 1 |a Zhang, Jiaqi  |e VerfasserIn  |4 aut 
700 1 |a Wang, Yalong  |e VerfasserIn  |4 aut 
700 1 |a Liu, Xi  |e VerfasserIn  |4 aut 
700 1 |a Ren, Yu  |e VerfasserIn  |4 aut 
700 1 |a Wang, Bin  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t European journal of medical research  |d London : BioMed Central, 2000  |g 30(2025), 1, Artikel-ID 249, Seite 1-11  |h Online-Ressource  |w (DE-627)375977775  |w (DE-600)2129989-4  |w (DE-576)281687544  |x 2047-783X  |7 nnas  |a Clinical-genomic characteristics of homologous recombination deficiency (HRD) in breast cancer application model for practice 
773 1 8 |g volume:30  |g year:2025  |g number:1  |g elocationid:249  |g pages:1-11  |g extent:11  |a Clinical-genomic characteristics of homologous recombination deficiency (HRD) in breast cancer application model for practice 
856 4 0 |u https://doi.org/10.1186/s40001-025-02520-8  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.webofscience.com/api/gateway?GWVersion=2&SrcAuth=GetFTR&SrcApp=WOS&DestURL=https%3A%2F%2Fct.prod.getft.io%2FY2xhcml2YXRlLHNwcmluZ2VyLGh0dHBzOi8vbGluay5zcHJpbmdlci5jb20vY29udGVudC9wZGYvMTAuMTE4Ni9zNDAwMDEtMDI1LTAyNTIwLTgucGRm.T51EBsIo7KqWOZLPHRmkrjAcBAEKpy-JHwn2nWEPTZQ&DestApp=GetFTR&SrcItemId=WOS:001460732800002&SrcAppSID=EUW1ED0F20QEs703P6yZ24jUlIiPZ&HMAC=kPvXZAIUEdXdTP94vAx6lRjq2Amv98vQgZ2UqLCcqWw%3D  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20251119 
993 |a Article 
994 |a 2025 
998 |g 1319494781  |a Ma, Nan  |m 1319494781:Ma, Nan  |p 4 
999 |a KXP-PPN1941614531  |e 4808718766 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Jinsui Du, Lizhe Zhu, Chenglong Duan, Nan Ma, Yudong Zhou, Danni Li, Jianing Zhang, Jiaqi Zhang, Yalong Wang, Xi Liu, Yu Ren, Bin Wang"]},"person":[{"roleDisplay":"VerfasserIn","display":"Du, Jinsui","role":"aut","family":"Du","given":"Jinsui"},{"role":"aut","display":"Zhu, Lizhe","roleDisplay":"VerfasserIn","given":"Lizhe","family":"Zhu"},{"given":"Chenglong","family":"Duan","role":"aut","roleDisplay":"VerfasserIn","display":"Duan, Chenglong"},{"given":"Nan","family":"Ma","role":"aut","display":"Ma, Nan","roleDisplay":"VerfasserIn"},{"family":"Zhou","given":"Yudong","display":"Zhou, Yudong","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Li, Danni","role":"aut","family":"Li","given":"Danni"},{"role":"aut","display":"Zhang, Jianing","roleDisplay":"VerfasserIn","given":"Jianing","family":"Zhang"},{"family":"Zhang","given":"Jiaqi","roleDisplay":"VerfasserIn","display":"Zhang, Jiaqi","role":"aut"},{"family":"Wang","given":"Yalong","display":"Wang, Yalong","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Liu","given":"Xi","display":"Liu, Xi","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Yu","family":"Ren","role":"aut","roleDisplay":"VerfasserIn","display":"Ren, Yu"},{"roleDisplay":"VerfasserIn","display":"Wang, Bin","role":"aut","family":"Wang","given":"Bin"}],"origin":[{"dateIssuedDisp":"April 7, 2025","dateIssuedKey":"2025"}],"title":[{"subtitle":"application model for practice","title":"Clinical-genomic characteristics of homologous recombination deficiency (HRD) in breast cancer","title_sort":"Clinical-genomic characteristics of homologous recombination deficiency (HRD) in breast cancer"}],"id":{"doi":["10.1186/s40001-025-02520-8"],"eki":["1941614531"]},"physDesc":[{"extent":"11 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"origin":[{"dateIssuedDisp":"2000-","dateIssuedKey":"2000","publisher":"BioMed Central ; Holzapfel","publisherPlace":"London ; Munich"}],"id":{"issn":["2047-783X"],"zdb":["2129989-4"],"eki":["375977775"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"European journal of medical research","subtitle":"official organ \"Deutsche AIDS-Gesellschaft\"","title_sort":"European journal of medical research"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 14.05.12"],"disp":"Clinical-genomic characteristics of homologous recombination deficiency (HRD) in breast cancer application model for practiceEuropean journal of medical research","recId":"375977775","corporate":[{"role":"isb","display":"Deutsche Aids-Gesellschaft","roleDisplay":"Herausgebendes Organ"}],"language":["eng"],"pubHistory":["Nachgewiesen 5.2000 -"],"part":{"year":"2025","issue":"1","pages":"1-11","volume":"30","text":"30(2025), 1, Artikel-ID 249, Seite 1-11","extent":"11"}}],"language":["eng"],"recId":"1941614531"} 
SRT |a DUJINSUIZHCLINICALGE7202